3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
9
Lymphoma, Non-Hodgkin
9
Lymphoma, B-Cell
5
Arthritis, Rheumatoid
5
Solid Tumors
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Colorectal Neoplasms
3
Ovarian Neoplasms
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Spondylitis, Ankylosing
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Mesothelioma
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Esophageal Neoplasms
1
Interventions
tocilizumab
1
otelixizumab
1
obinutuzumab
1
glofitamab
1
Oxaliplatin
1
Gemcitabine
1
Gelsolin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Cytokine Release Syndrome
×
tocilizumab
×
Clear all
NCT07609940
2026-05-27
POPLIN
Regeneron Pharmaceuticals
Phase 4
Not yet recruiting
30 enrolled